Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy

Oriot, Philippe; Hermans, Michel P.; Selvais, P. L.; Buysschaert, Martin; Tribonnière, Xavier de la

doi:10.1016/j.ando.2011.04.003

Cited by 19 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single case report shows that treatment with a combination of exenatide, metformin, and repaglinide improved insulin sensitivity and led to significant weight loss in a diabetic HIV patient on HAART [127]. GLP-1 agonists (like exenatide) control diabetes through several mechanisms, including glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion, slowing of gastric emptying, appetite suppression, and resulting weight loss [128].…”

Section: Managementmentioning

confidence: 99%

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

Gutierrez

Balasubramanyam

2011

Endocrine

View full text Add to dashboard Cite

HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased prevalence of impaired glucose tolerance, diabetes mellitus and cardiometabolic syndrome. While much attention has been focused on the lipid and cardiovascular disorders, few investigations have attempted to characterize the prevalence, incidence, etiology, mechanisms and management of glycemic disorders in HIV patients. In this review, we have focused specifically on a comprehensive assessment of dysglycemia in the context of HIV infection and HAART.

show abstract

Section: Managementmentioning

confidence: 99%

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

Gutierrez

Balasubramanyam

2011

Endocrine

View full text Add to dashboard Cite

show abstract

“…Within 1 year of treatment with exenatide in combination with metformin and repaglinide, this patient responded with weight loss and improved glucose control by increase in insulin sensitivity. These results are promising, and possibly exenatide can be a new treatment option for type 2 diabetic and HIV-induced LD patients on protease inhibitors [25].…”

Section: Clinical Managementmentioning

confidence: 97%

Lipodystrophy: Syndrome of severe insulin resistance

Bindlish

Presswala

Schwartz

2015

Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

“…Glucagon-like peptide-1 (GLP-1) analogues, including formulations of exenatide and liraglutide, increase glucose-dependent insulin secretion, decrease gluconeogenesis, promote β-cell proliferation and differentiation, decrease gastric emptying time, and reduce food intake [ 187 ]. Substitution of exenatide for insulin in combination with metformin and repaglinide in ARV-treated HIV-infected patients resulted in weight loss, improved insulin sensitivity and β-cell function [ 188 ].…”

Section: Reducing the Risk Of Hiv-associated Cardiovascular Diseasementioning

confidence: 99%

Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease

Chastain

Henderson

Stover

2015

TOAIDJ

View full text Add to dashboard Cite

Risk and manifestations of cardiovascular disease (CVD) in patients infected with human immunodeficiency virus (HIV) will continue to evolve as improved treatments and life expectancy of these patients increases. Although initiation of antiretroviral (ARV) therapy has been shown to reduce this risk, some ARV medications may induce metabolic abnormalities, further compounding the risk of CVD. In this patient population, both pharmacologic and nonpharmacologic strategies should be employed to treat and reduce further risk of CVD. This review summarizes epidemiology data of the risk factors and development of CVD in HIV and provides recommendations to manage CVD in HIV-infected patients.

show abstract

Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy

Cited by 19 publications

References 9 publications

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

Lipodystrophy: Syndrome of severe insulin resistance

Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease

Contact Info

Product

Resources

About